drugset / Trial / NCT01658826

Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes

NCT01658826

RandomizedCrossoverTriple-blindPrevention

Summary

The aim of the study is to evaluate the safety and efficacy of "AIC316 (pritelivir)" 100 mg once daily compared to valacyclovir 500 mg once daily for the prevention of HSV-2 genital shedding.

Timeline

Start
2012-10
Primary completion
2013-05
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pritelivir Small molecule 100 mg Oral
Subject Valacyclovir Unknown 500 mg Oral

Indications